Colonic ulceration in a patient with renal disease and hyperkalemia: A drug commonly used to treat hyperkalemia has the potential to damage the GI mucosa, especially in surgical patients or patients with end-stage renal disease

Journal of the American Academy of Physician Assistants

Volumn 25, Issue 10, 2012, Pages 34-38

  Chelcun, Johanna L ^a   Sable, Robert A ^b   Friedman, Kenneth ^b  

^a QUINNIPIAC UNIVERSITY   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATION EXCHANGE RESIN; POLYSTYRENE DERIVATIVE; POLYSTYRENESULFONIC ACID;

ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; COLITIS; COLON DISEASE; DRUG EFFECT; HUMAN; HYPERKALEMIA; INTESTINE MUCOSA; MALE; MIDDLE AGED; ULCER;

CATION EXCHANGE RESINS; COLITIS; COLONIC DISEASES; HUMANS; HYPERKALEMIA; INTESTINAL MUCOSA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYSTYRENES; ULCER;

EID: 84871890823     PISSN: 15471896     EISSN: 08937400     Source Type: Journal    
DOI: 10.1097/01720610-201210000-00008     Document Type: Article

References (9)

1. Gerstman BB, Kirkman R, Platt R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am J Kidney Dis. 1992;20(2):159-161.
2. Rashid A, Hamilton SR. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. Am J Surg Pathol. 1997;21(1):60-69.
3. Abraham SC, Bhagavan BS, Lee LA, et al. Upper gastrointestinal tract injury in patients receiving Kayexalate (sodium polystyrene sulfonate) in sorbitol. Am J Surg Pathol. 2001;25(5):637-644.
4. Scherr L, Ogden DA, Mead AW, et al. Management of hyperkalemia with a cation-exchange resin. N Engl J Med. 1961;264(3):115-119.
5. McGowan CE, Saha S, Chu G, et al. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J. 2009;102(5):493-497.
6. Roy-Chaudhury P, Meisels IS, Freedman S, et al. Combined gastric and ileocecal toxicity (serpiginous ulcers) after oral Kayexalate in sorbitol therapy. Am J Kidney Dis. 1997;30(1):120-122.
7. Sevastos N, Theodossiades G, Efstathiou S, et al. Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. J Lab Clin Med. 2006;147(3):139-144.
8. Stankovic AK, Smith S. Elevated serum potassium values: the role of preanalytic variables. Am J Clin Pathol. 2004;121(suppl 1):S105-S112.
9. Food and Drug Administration. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). January 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ ucm186845.htm. Published January 2011. Updated February 17, 2011. Accessed September 1, 2012.